Tremfya and Stelara are two Johnson & Johnson IL-23 pathway biologics for moderate-to-severe ulcerative colitis. Stelara has been the established UC option since its UNIFI-based approval, while Tremfya received UC approval in 2024 based on the QUASAR and ASTRO trials. The drugs differ in mechanism. Tremfya selectively blocks IL-23 through p19, while Stelara blocks both IL-12 and IL-23 through p40. For Crohn's, GALAXI 2 and 3 demonstrated Tremfya's superiority over Stelara on endoscopic endpoints. UC patients often ask whether similar logic applies to their disease. This guide walks through the tremfya vs stelara ulcerative colitis decision.
p19 vs p40 IL-23 Targeting
Tremfya (guselkumab) binds the p19 subunit of IL-23, selectively blocking only IL-23. Stelara (ustekinumab) binds the p40 subunit shared by IL-12 and IL-23, blocking both cytokines. IL-23 is the dominant driver of the Th17 inflammatory pathway that fuels UC, so p19 selectivity is designed to deliver the clinical benefit of ustekinumab without blocking IL-12. The guselkumab vs ustekinumab UC rationale is that leaving IL-12 intact preserves immune surveillance functions that may matter for long-term safety, while IL-23 blockade alone handles the UC-relevant inflammation. Whether this theoretical advantage produces measurable clinical differences in UC has not been tested head-to-head, but QUASAR, ASTRO, and UNIFI give us meaningful indirect comparison data.
QUASAR and ASTRO: Tremfya UC Evidence
QUASAR was the pivotal phase 3 trial of guselkumab for UC. The induction portion randomized biologic-naive and biologic-experienced UC patients to IV guselkumab induction or placebo, with the maintenance portion evaluating subcutaneous maintenance. QUASAR showed clinical remission at week 12 in 23% of guselkumab patients compared with 8% on placebo, with endoscopic improvement and symptomatic remission also significantly better on active drug. Through week 44 of maintenance, patients who responded to induction and continued guselkumab maintained higher rates of remission than placebo. ASTRO evaluated a fully subcutaneous induction pathway for guselkumab in UC, allowing patients to skip IV induction entirely. Stelara's UNIFI established similar UC efficacy patterns with IV induction and SC maintenance.
Indirect Efficacy Comparison
No head-to-head trial has compared guselkumab and ustekinumab in UC. Cross-trial comparisons using network meta-analysis suggest similar clinical remission rates between the two drugs in UC, with some evidence favoring p19 selectivity on endoscopic endpoints. The Crohn's GALAXI data, which did directly compare the drugs, showed superiority of guselkumab on endoscopic outcomes. Whether that pattern translates to UC remains open. Real-world registries and post-marketing studies over the next few years should clarify whether Tremfya's endoscopic advantage in Crohn's carries over to UC. In the meantime, most gastroenterologists consider both drugs reasonable choices for UC patients who are weighing an IL-23 pathway biologic.
Onset of Action
Both drugs produce clinically meaningful response by week 12, consistent with other IL-23 pathway biologics. Tremfya's QUASAR showed significant differences from placebo as early as week 4 in some outcomes. Stelara's UNIFI showed similar early response patterns after IV induction. Neither drug is as fast in UC as an anti-TNF, a JAK inhibitor, or a sphingosine-1-phosphate modulator. For UC patients with severe, active symptoms who need rapid symptom control, a faster-acting agent may fit better initially. For patients in less acute states or those who have already failed an anti-TNF, Tremfya and Stelara both offer reasonable response timelines.
Administration and Dosing Flexibility
Tremfya offers uniquely flexible administration for UC. Patients can choose either IV induction (200 mg at weeks 0, 4, and 8) or fully subcutaneous induction (400 mg at weeks 0, 4, and 8) based on preference and access. Maintenance is 100 mg SC every 8 weeks or 200 mg SC every 4 weeks. Stelara uses a single weight-based IV induction dose, then 90 mg SC every 8 weeks, with no all-SC induction option in UC. For UC patients who want to avoid infusion centers entirely, Tremfya's SC induction pathway is a meaningful practical advantage. For patients who prefer a single IV induction dose, Stelara's schedule is slightly simpler up front.
Safety and Tolerability
Both drugs have favorable safety profiles relative to anti-TNFs. Stelara's long-term UC safety data shows lower infection rates than infliximab or adalimumab. Tremfya's UC safety data is shorter but consistent with the broader class profile and with its extensive psoriasis and psoriatic arthritis experience. Serious infection rates in QUASAR were similar to placebo. For tremfya vs stelara UC side effects, injection-site reactions, upper respiratory infections, and headache are the most common events with both drugs. Both carry boxed warnings related to serious infections, and both require TB and hepatitis B screening before starting.
Choosing With Your GI
For UC patients choosing between Tremfya and Stelara, the decision today rests on indirect trial comparisons, administration preferences, and cost. Tremfya's p19 selectivity may deliver stronger endoscopic outcomes (extrapolating from Crohn's GALAXI data), and its fully SC induction option eliminates infusion center visits. Stelara has a longer UC track record, biosimilar availability as of 2025, and often lower out-of-pocket costs depending on insurance plan. Ask your GI how response will be measured after induction (typically week 12 to 16 for both drugs), what to do if symptoms persist, and whether your plan's coverage favors one drug. A log of stool frequency, urgency, blood, and any new symptoms between visits gives your care team the data to recognize partial response or early loss of response before a full flare.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.